LL-37 Research Documentation Best Practices

Sound documentation for LL-37 comes down to four record sets: a lot-specific certificate of analysis you can verify at the source, an unbroken chain of custody from supplier to shelf, storage and handling logs tied to that same lot number, and a supplier qualification file you refresh on a set schedule. Everything else is detail. The working test is simple — pull a vial at random and see whether you can produce its COA, its purchase record, and its storage history within a few minutes. If you can, your system works. If you can't, no internal policy will paper over the gap, and no supplier can fix it for you after the fact.

This matters more for a compound like LL-37 than for a commodity input, because the peptide's identity and purity are not things a buyer can eyeball. LL-37 is the C-terminal fragment of the human cathelicidin precursor hCAP18, a cationic, amphipathic sequence that has drawn substantial attention in innate immunity research literature. Whatever a downstream researcher is studying, the credibility of that work rests on being able to say, with evidence, exactly what was in the vial.

Documentation is a sourcing decision before it is a filing decision

Most buyers treat recordkeeping as something that starts after delivery. It doesn't. The quality of your records is capped by what your supplier is willing to hand over, and that ceiling is set the moment you place the first order.

A supplier who publishes lot-level analytical results creates a paper trail you can extend. A supplier who emails a generic PDF on request — undated, unattributed to a lot, with no method named — hands you a dead end. You can build the most disciplined internal log in the category on top of that document and it will still fail the first serious question anyone asks, because the foundation record proves nothing.

This is why experienced wholesale buyers evaluate documentation practices during supplier selection rather than after. The questions are straightforward: Is the COA tied to a specific lot number? Is it dated? Does it name the analytical methods used? Can I see it before I buy, without asking? Is it free, or is it treated as an upsell? A supplier that charges separately for test results is telling you something about how they view the relationship between price and proof.

The records that should exist before a vial reaches your shelf

A complete pre-shelf file is not long, but each piece does distinct work.

Supplier qualification record. Who you buy from, what you verified about them, and when. Keep the evidence, not just the conclusion — screenshots or saved copies of published testing standards, the terms you were quoted, and the name of the person you dealt with. Revisit it on a fixed cadence rather than when something goes wrong.

Purchase documentation with lot numbers. An invoice that lists quantity and compound but not lot is half a record. Insist on lot-level detail on the paperwork, and reconcile the lots listed against the lots physically received. Discrepancies between the two are the single most common quiet failure in peptide inventory.

Lot-matched certificate of analysis. Not a sample COA. Not a COA for a prior lot. The one that corresponds to the vials in the box.

Receiving condition notes. Date received, condition of the shipment, packaging integrity, whether cold chain materials arrived intact if applicable. Brief is fine; absent is not.

Labeling verification. Confirm each unit is labeled for research use only and that the label carries the compound name, quantity, and lot. If labeling is inconsistent across a shipment, log it before the vials disperse into storage.

Reading a certificate of analysis instead of filing it

A COA is only useful if someone actually reads it. For a cationic peptide, several panels carry real weight, and a buyer should know what each one is for.

Identity confirmation, typically by mass spectrometry, establishes that the sequence synthesized is the sequence ordered. Purity by HPLC quantifies how much of the material is the target peptide versus process-related impurities — deletion sequences, truncations, and similar byproducts of solid-phase synthesis. Water content matters because lyophilized peptide mass includes residual moisture, and it affects how net peptide content should be interpreted. Counterion content, usually acetate from purification, is a similar accounting question. Residual solvents and heavy metals speak to how cleanly the synthesis and purification were run. Bacterial endotoxin and bioburden panels address microbiological quality.

The practical instruction is this: record which panels appeared on the COA for each lot, not just the headline purity number. When two lots of the same compound behave differently in a research setting, the explanation is usually somewhere in the panels nobody wrote down.

Watch for what is missing as carefully as what is present. A COA with a purity figure and nothing else is a marketing document wearing a lab coat. A COA that names no method, no test date, and no testing party cannot be independently checked. And a COA you cannot see until after you have committed to buy is, by design, not a verification tool.

A minimum record set worth holding

Keeping the chain intact after receiving

Once material is on the shelf, documentation shifts from verification to continuity. The goal is that any unit can be traced forward and backward without guesswork.

Storage conditions should be logged against the supplier's stated conditions for that lot rather than against a general rule of thumb — different presentations and different lots may carry different guidance, and the supplier's specification is the reference point. Where handling steps are part of a research protocol, record that they occurred, who performed them, and when. The content of the protocol belongs to the researcher; the fact that it happened belongs in your records.

Transfers matter more than most operations realize. Every unit that leaves your inventory should have a destination recorded against a lot number. Reconcile physical count to recorded count on a set schedule, and treat variances as events to investigate rather than rounding errors to absorb. Document disposals and damaged units with the same seriousness as sales — an unexplained gap in inventory is far harder to answer for than a documented loss.

Finally, decide on a retention period and write it down. Records that exist but were quietly discarded eighteen months later are functionally the same as records that never existed.

Compliance questions that belong with your counsel

This section is informational and is not legal advice. Research compounds sit in a regulatory landscape that varies by jurisdiction and by the nature of the business handling them, and general articles cannot resolve those questions for your specific operation.

The useful move is to arrive at your attorney's office with the right questions rather than assumptions. Among them: How should research-use-only material be labeled and represented in our particular business model? What recordkeeping obligations, if any, attach to us as a reseller versus as an end user? Are there state-level requirements or professional board expectations relevant to how our business is licensed? What representations about these compounds are we permitted to make in our own marketing, and which are we not? How long must we retain purchase and distribution records, and in what form?

Do not rely on what a supplier, a forum, or a competitor asserts about legality in your state. Positions vary, they change, and the consequences land on you rather than on whoever told you it was fine. Your state board and your own counsel are the only appropriate sources for a conclusion.

What Real Peptides does differently

Real Peptides is built around the assumption that a wholesale buyer should be able to check the work rather than take it on trust.

Every batch is tested to a 99%+ HPLC purity standard, and each batch runs through 7-panel testing rather than a single purity figure. Certificates of analysis are publicly verifiable — a prospective partner can pull up the lab results and read them before contacting anyone, which removes the awkward step of requesting proof from a supplier who has not yet earned the benefit of the doubt. COAs are not an add-on, not a paid extra, and not something produced only when a buyer pushes.

Fulfillment is handled in the US, with orders shipping in 5–7 days, which makes receiving windows predictable enough to log against without treating every shipment as an exception. The Wholesale Partner Program runs on a 3-step application, so a qualified business can establish an account without an opaque back-and-forth about whether pricing exists.

The contrast worth drawing is not with any particular company but with a set of practices buyers encounter regularly: pricing that only appears after a sales call, testing that cannot be independently confirmed, and analytical documentation treated as a revenue line rather than a baseline. A supplier whose evidence is public is a supplier whose records can safely become the first page of yours.

Where this leaves a wholesale buyer

If you are stocking research peptides for a med spa, clinic, telehealth operation, or reseller catalog, your documentation system is only as good as the analytical evidence at its foundation. Start there, verify it before you commit, and build your internal logs on top of something that will hold. Businesses ready to formalize sourcing on that basis can apply through the Real Peptides Wholesale Partner Program, where pricing, testing standards, and COAs are visible from the outset.

Buyers reviewing catalog breadth alongside documentation standards can browse the popular peptides range, the growth factor and tissue signaling research collection, and the gastrointestinal and epithelial research compounds at Real Peptides. All compounds are supplied for research use only.